A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD

NCT02624778 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

61

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer Disease

Interventions

BIOLOGICAL: LY3002813
DRUG: Placebo

Sponsor

Eli Lilly and Company